Innovations in oligonucleotide drug delivery

被引：65

作者：

Lysik, MA

Wu-Pong, S

机构：

[1] Midwestern Univ, Coll Pharm, Dept Pharmaceut Sci, Glendale, AZ USA

[2] Virginia Commonwealth Univ, Med Coll Virginia, Sch Pharm, Dept Pharmaceut, Richmond, VA 23298 USA

来源：

JOURNAL OF PHARMACEUTICAL SCIENCES | 2003年 / 92卷 / 08期

关键词：

oligonucleotide; uptake; delivery; liposomes; carrier-mediated delivery; novel delivery methods;

D O I：

10.1002/jps.10399

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Oligonucleotides (ONs) are a new class of therapeutic compounds under investigation for the treatment of a variety of disease states, such as cancer and HIV, and for FDA approval of an anti-CMV retinitis antisense molecule (Vitravene(TM), Isis Pharmaceuticals). However, these molecules are limited not only by poor cellular uptake, but also by a general lack of understanding regarding the mechanism(s) of ON cellular uptake. As a result, various delivery vehicles have been-developed that circumvent the proposed mechanism of uptake, endocytosis, while improving target specific delivery and/or drug stability. This review describes various traditional and novel delivery mechanisms that have been employed to improve ON cellular delivery, cost effectiveness, and therapeutic efficacy. (C) 2003 Wiley-Liss, Inc. and the American Pharmacists Association.

引用

页码：1559 / 1573

页数：15

共 127 条

[1] Beta-cyclodextrin derivatives as carriers to enhance the antiviral activity of an antisense oligonucleotide directed toward a coronavirus intergenic consensus sequence [J].